ImmunoCellular Therapeutics Expands Phase 2 Trial For Brain Cancer Treatment
ImmunoCellular Therapeutics has expanded the number of sites for its phase two clinical trial ofa potential vaccine treatment for brain cancer.
feature2
Navigating the Perilous Road: A Special Panel On Regulatory and Reimbursement Issues
A panel at OneMedForum NY 2011 will explore strategic planning considerations in the process of getting approval and reimbursement.
Rib-X Pharmaceuticals’ Nobel Prize Winning Platform Combats Serious Infections
The antibiotic market is expected to reach $45 billion by 2012 driven by the deficiencies of currently available antibiotics.
Small Bone Innovations Addresses Unmet Needs in Joint Replacement
Orthopedic companies have focused on developing devices for large bone trauma, leaving the small bone and joint field lacking.
Emergent BioSolutions Acquires Rights To Lymphoma Drug
Emergent BioSolutions has acquired the rights to Zanolimumab, an investigational and late-stage antibody cancer therapy.
Hepregen Awarded $500,000 Massachusetts Life Sciences Center Grant
Hepregen, a leading provider of bioengineered solutions that increase success in drug development, was awarded a $500,000 grant as part of the Small Business Matching Grants program
Phytoceuticals Heals Wounds Through An Easy To Use Spray
This is a new solution that is poised to become the standard of care in wound management because of effective speed, ease of use and cost savings.
GlySure’s Technology May Break Barrier For Tight Control And Automated Glucose Monitoring
GlySure’s technology enables a healthcare facility to implement tight glycemic control and intensive insulin therapy.
YM BioSciences Receives Orphan Drug Designation In EU For Myelofibrosis Treatment
YM BioSciences has received orphan drug designation from the European Commission for CYT387, a treatment for myelofibrosis, a type of chronic leukemia.
Advanced Cardiac Therapeutics Studies Innovative Catheter System To Treat Arrythmias
ACT recently announced that the first patients have been enrolled in a CE Mark clinical trial of the safety and performance of the company’s TEMPASURE cardiac ablation catheter.